Een onderzoek naar Suvorexant (MK-4305) voor de behandeling van slapeloosheid bij deelnemers met een opioïdengebruiksstoornis (MK-4305-098)
Een fase 3, multicenter, gerandomiseerde, dubbelblinde, placebogecontroleerde studie om de werkzaamheid en veiligheid van Suvorexant voor de behandeling van slapeloosheid bij deelnemers met een opioïdengebruiksstoornis te evalueren
People with opioid use disorder (OUD) can have trouble falling or staying asleep. Researchers want to know if suvorexant will help people with OUD fall asleep and stay asleep. The goal of this study is to learn about the safety of suvorexant and how well people tolerate it. Researchers also want to learn if suvorexant helps people sleep longer compared to people who take placebo. A placebo looks like the study medicine but has no actual study medicine in it.
Studie Overzicht
Toestand
Conditie
Interventie / Behandeling
Studietype
Inschrijving (Geschat)
Fase
- Fase 3
Contacten en locaties
Studiecontact
- Naam: Toll Free Number
- Telefoonnummer: 1-888-577-8839
- E-mail: Trialsites@msd.com
Studie Locaties
-
-
California
-
Garden Grove, California, Verenigde Staten, 92845
- Werving
- Cenexel CNS ( Site 2012)
-
Contact:
- Study Coordinator
- Telefoonnummer: 866-787-4257
-
-
Connecticut
-
New Haven, Connecticut, Verenigde Staten, 06520
- Werving
- Yale University School of Medicine ( Site 1003)
-
Contact:
- Study Coordinator
- Telefoonnummer: 203-785-3627
-
-
Florida
-
Bradenton, Florida, Verenigde Staten, 34205
- Werving
- Bradenton Research Center ( Site 2021)
-
Contact:
- Study Coordinator
- Telefoonnummer: 941-708-0005
-
-
Georgia
-
Savannah, Georgia, Verenigde Staten, 31405
- Werving
- CenExel iResearch, LLC ( Site 2010)
-
Contact:
- Study Coordinator
- Telefoonnummer: 912-744-0800
-
-
Maryland
-
Baltimore, Maryland, Verenigde Staten, 21224
- Werving
- Johns Hopkins University ( Site 1001)
-
Contact:
- Study Coordinator
- Telefoonnummer: 443-216-9237
-
-
New Jersey
-
Marlton, New Jersey, Verenigde Staten, 08053
- Werving
- Hassman Research Institute Marlton Site ( Site 2005)
-
Contact:
- Study Coordinator
- Telefoonnummer: 856-261-6420
-
-
Oklahoma
-
Oklahoma City, Oklahoma, Verenigde Staten, 73112
- Werving
- The Rivus Wellness & Research Institute ( Site 2014)
-
Contact:
- Study Coordinator
- Telefoonnummer: 405-607-2233
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Verenigde Staten, 19104
- Werving
- Penn Medicine University of Pennsylvania Health System- Center for Studies of Addiction ( Site 1006)
-
Contact:
- Study Coordinator
- Telefoonnummer: 215-222-3200
-
-
Rhode Island
-
Providence, Rhode Island, Verenigde Staten, 02906
- Werving
- Butler Hospital ( Site 1002)
-
Contact:
- Study Coordinator
- Telefoonnummer: 401-455-6440
-
-
South Carolina
-
Charleston, South Carolina, Verenigde Staten, 29403
- Werving
- Medical University of South Carolina ( Site 1005)
-
Contact:
- Study Coordinator
- Telefoonnummer: 843-792-4636
-
-
Texas
-
DeSoto, Texas, Verenigde Staten, 75115
- Werving
- Adams Clinical Dallas ( Site 2007)
-
Contact:
- Study Coordinator
- Telefoonnummer: 972-283-6286
-
Houston, Texas, Verenigde Staten, 77043
- Werving
- Memorial Hermann Village ( Site 2001)
-
Contact:
- Study Coordinator
- Telefoonnummer: 281-369-5765
-
-
Virginia
-
Richmond, Virginia, Verenigde Staten, 23219
- Werving
- VCU Institute for Drug and Alcohol Studies ( Site 1004)
-
Contact:
- Study Coordinator
- Telefoonnummer: 804-827-3784
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
The main inclusion criteria include but are not limited to the following:
- Has a primary diagnosis of OUD according to Diagnostic and Statistical Manual of Mental Disorder, 5th Edition (DSM-5), and confirmed through the Mini International Neuropsychiatric Interview (MINI).
- Is on a verified, stable dose of medications for opioid use disorder (MOUD) treatment.
- Meets DSM-5 criteria for the diagnosis of Insomnia Disorder
- Has a regular bedtime between 8 PM (20:00) and 1 AM (01:00) and is willing to maintain it for the duration of the study.
- Has not used opioids for a period of at least 4 weeks before entering the study.
Exclusion Criteria:
The main exclusion criteria include but are not limited to the following:
- Has current uncontrolled major co-morbid psychiatric illness including major depressive disorder, bipolar disorder, schizophrenia, or any psychiatric condition with psychotic features.
- Has current diagnosis or history within 5 years of any of the following: narcolepsy, sleep paralysis, severe periodic limb movement disorder, restless leg syndrome, cataplexy, circadian rhythm sleep disorder, parasomnia including nightmare disorder, sleep terror disorder, sleepwalking disorder, rapid eye movement (REM) behavior disorder, significant degree of sleep-related breathing disorder, excessive daytime sleepiness (EDS), or primary hypersomnia.
- Is at imminent risk of self-harm.
- Has a known history of stroke that may confound the diagnosis of insomnia.
- Has a clinically significant movement disorder such as akinesia.
- Has a history of hepatitis or live disease.
- Has habitual use of central nervous system (CNS)-depressants or stimulants that may be responsible for the participant's disturbed sleep.
- Has a history of malignancy, ≤3 years prior to start of study, with the exception of nonmelanoma skin cancer, prostate cancer or localized carcinoma in situ of the cervix.
- Has a history of hypersensitivity to more than 3 chemical classes of drugs, including prescription and over-the-counter medications.
- Has donated blood products or had phlebotomy within 8 weeks prior to start of study.
- Has a history of transmeridian travel within 2 weeks prior to start of study.
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: Gerandomiseerd
- Interventioneel model: Parallelle opdracht
- Masker: Verdrievoudigen
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
|---|---|
|
Experimenteel: Suvorexant
Participants receive 10 mg of suvorexant for the first three nights, increased to 20 mg of suvorexant nightly thereafter at the investigator's discretion, for up to approximately 8 weeks. |
Oral Tablet
Andere namen:
|
|
Placebo-vergelijker: Placebo
Participants receive suvorexant-matching placebo for up to approximately 8 weeks. |
Oral Tablet |
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Change from Baseline in Total Sleep Time at Week 8
Tijdsspanne: Baseline and Week 8
|
Total sleep time will be measured in a sleep laboratory by polysomnography at the participant's habitual bedtime. Change from baseline in total sleep time at Week 8 will be reported. |
Baseline and Week 8
|
|
Number of Participants Who Experience One or More Adverse Events (AEs)
Tijdsspanne: Up to approximately 10 weeks
|
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. |
Up to approximately 10 weeks
|
|
Number of Participants Who Experience One or More Serious Adverse Events (SAEs)
Tijdsspanne: Up to approximately 10 weeks
|
An SAE is any untoward medical occurrence that at any dose results in death, is life threatening, requires or prolongs inpatient hospitalization, results in persistent or significant disability or incapacity, is a congenital anomaly or birth defect or is another important medical event deemed such by medical or scientific judgement. |
Up to approximately 10 weeks
|
|
Number of Participants Who Discontinue Study Treatment Due to an AE
Tijdsspanne: Up to approximately 8 weeks
|
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. |
Up to approximately 8 weeks
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Change from Baseline in Wakefulness after Persistent Sleep Onset at Week 8
Tijdsspanne: Baseline and Week 8
|
Wakefulness after persistent sleep onset will be measured in a sleep laboratory by polysomnography at the participant's habitual bedtime. Change from baseline in wakefulness after persistent sleep onset at Week 8 will be reported. |
Baseline and Week 8
|
|
Number of Participants Who are Positive for Substance Abuse at Day 1
Tijdsspanne: Day 1
|
A positive assessment for substance abuse at Day 1 is defined as either a positive urine drug test for opioids and other nonmedical substances including fentanyl, cocaine, amphetamines, benzodiazepines, and cannabis OR a positive response on the Substance Use History (SUH) Since Last Assessment questionnaire. The Substance Use History Questionnaire (SUH) has been developed specifically for this study. This is a self-reported questionnaire used to obtain a variety of quantitative estimates of cannabis, alcohol, and other nonmedical substance use. The SUH Since Last Assessment Questionnaire will be used to assess nonmedical substance and alcohol use since the previous study visit. |
Day 1
|
|
Number of Participants Who are Positive for Substance Abuse at Day 4
Tijdsspanne: Day 4
|
A positive assessment for substance abuse at Day 4 is defined as either a positive urine drug test for opioids and other nonmedical substances including fentanyl, cocaine, amphetamines, benzodiazepines, and cannabis OR a positive response on the Substance Use History (SUH) Since Last Assessment questionnaire. The Substance Use History Questionnaire (SUH) has been developed specifically for this study. This is a self-reported questionnaire used to obtain a variety of quantitative estimates of cannabis, alcohol, and other nonmedical substance use. The SUH Since Last Assessment Questionnaire will be used to assess nonmedical substance and alcohol use since the previous study visit. |
Day 4
|
|
Number of Participants Who are Positive for Substance Abuse at Week 2
Tijdsspanne: Week 2
|
A positive assessment for substance abuse at Week 2 is defined as either a positive urine drug test for opioids and other nonmedical substances including fentanyl, cocaine, amphetamines, benzodiazepines, and cannabis OR a positive response on the Substance Use History (SUH) Since Last Assessment questionnaire. The Substance Use History Questionnaire (SUH) has been developed specifically for this study. This is a self-reported questionnaire used to obtain a variety of quantitative estimates of cannabis, alcohol, and other nonmedical substance use. The SUH Since Last Assessment Questionnaire will be used to assess nonmedical substance and alcohol use since the previous study visit. |
Week 2
|
|
Number of Participants Who are Positive for Substance Abuse at Week 4
Tijdsspanne: Week 4
|
A positive assessment for substance abuse at Week 4 is defined as either a positive urine drug test for opioids and other nonmedical substances including fentanyl, cocaine, amphetamines, benzodiazepines, and cannabis OR a positive response on the Substance Use History (SUH) Since Last Assessment questionnaire. The Substance Use History Questionnaire (SUH) has been developed specifically for this study. This is a self-reported questionnaire used to obtain a variety of quantitative estimates of cannabis, alcohol, and other nonmedical substance use. The SUH Since Last Assessment Questionnaire will be used to assess nonmedical substance and alcohol use since the previous study visit. |
Week 4
|
|
Number of Participants Who are Positive for Substance Abuse at Week 8
Tijdsspanne: Week 8
|
A positive assessment for substance abuse at Week 8 is defined as either a positive urine drug test for opioids and other nonmedical substances including fentanyl, cocaine, amphetamines, benzodiazepines, and cannabis OR a positive response on the Substance Use History (SUH) Since Last Assessment questionnaire. The Substance Use History Questionnaire (SUH) has been developed specifically for this study. This is a self-reported questionnaire used to obtain a variety of quantitative estimates of cannabis, alcohol, and other nonmedical substance use. The SUH Since Last Assessment Questionnaire will be used to assess nonmedical substance and alcohol use since the previous study visit. |
Week 8
|
|
Number of Participants with Positive Urine Drug Screen
Tijdsspanne: Day 1, Day 4, Week 2, Week 4, Week 8
|
A positive urine drug screen is defined as urine drug test positive for opioids and other nonmedical substances including fentanyl, cocaine, amphetamines, benzodiazepines, and cannabis |
Day 1, Day 4, Week 2, Week 4, Week 8
|
Medewerkers en onderzoekers
Sponsor
Onderzoekers
- Studie directeur: Medical Director, Merck Sharp & Dohme LLC
Publicaties en nuttige links
Nuttige links
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Primaire voltooiing (Geschat)
Studie voltooiing (Geschat)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Aanvullende relevante MeSH-voorwaarden
Andere studie-ID-nummers
- 4305-098
- MK-4305-098 (Andere identificatie: MSD)
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Beschrijving IPD-plan
https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .